Faculty
We are delighted to confirm the following international faculty for the 2026 SABR Symposium.
Houda Bahig
Dr. Houda Bahig, MD, PhD, is a radiation oncologist at the Centre hospitalier de l’Université de Montréal and Associate Professor at Université de Montréal. She specializes in SBRT and precision radiation oncology, with a focus on head and neck and lung cancers.
Dr. Bahig leads multiple investigator-initiated clinical trials evaluating head and neck SBRT, treatment de-escalation strategies, adaptive radiotherapy, immuno-radiotherapy combinations, and radiotherapy in patients with interstitial lung disease. She also leads a translational research laboratory whose program integrates radiomics, artificial intelligence, and multi-omics biomarkers to personalize radiation treatment, reduce toxicity, and optimize oncologic outcomes.
Melvin Chua
Dr. Chua a Clinician-Scientist at the National Cancer Centre Singapore (NCCS) and the Duke-NUS Medical School. He is the Head of Department and Senior Consultant for the Department of Head and Neck and Thoracic Radiation Oncology, Principal Investigator of the Precision Radiotherapeutics and Oncology Programme (PROP; and Director of the Data and Computational Science Hub at NCCS. He is currently Associate Professor (On Tenure) of Duke-NUS Medical School, Singapore; and Visiting Professor of the Zhongnan Hospital of Wuhan University, China.
His work is supported by several National grants including: (1) the NMRC CSA (Senior Investigator-category); (2) the NMRC Open Fund Large Collaborative Grant (OF-LCG); and (3) the NMRC Centre Grant, as well as large philanthropic donations, notably from the Goh Foundation to Proton Therapy Research, the Tibore Foundation to the Kua Hong Pak Head and Neck Cancer Research Programme, and the Singapore Rubber Miller Association to the Cancer and Data Science Programme. His key research focus areas are: (1) Developing a comprehensive nasopharyngeal carcinoma clinical and translational research programme that leverages on innovative designs of phase 2-3 trials, a multi-dimensional, deeply-annotated clinical-molecular database, coupled with broad-scale computational genomics approaches for biomarker discoveries; and (2) A translational radiation research programme that leverages on bench-to-bedside expertise to understand the mechanistic pathways of radiation resistance, and to develop new treatment regimens to target these molecular vulnerabilities.
Stefanie Corradini
Prof. Stefanie Corradini, MD, is a radiation oncologist and Professor of Radiotherapy at the Friedrich‑Alexander‑University Erlangen‑Nürnberg (FAU), where she has served since October 2025 as Director of the Department of Radiation Oncology and Chair of Radiotherapy.
Prof. Corradini is internationally recognised for her expertise in MR‑guided radiotherapy, high‑precision stereotactic treatments (SABR/SBRT), and brachytherapy, and has contributed to advancing treatment of complex or inoperable cancers through novel high‑dose, image‑guided approaches that maximise tumour control while minimising toxicity. She has led major research efforts, including the world’s largest study on radiotherapy for cardiac tumours, and continues to collaborate internationally on innovations in motion management, automation, and AI‑supported radiation therapy.
Her research portfolio spans clinical radiation oncology, MR‑guided therapy development, high‑risk lung SABR, and image‑guided brachytherapy, with numerous publications across high‑impact journals and contributions to field‑defining textbooks. Recent work includes leading a multi‑institutional analysis of single‑fraction MR‑guided SABR demonstrating excellent local control with low toxicity.
Prof. Corradini is a strong advocate for integrating cutting‑edge technology with personalised, compassionate patient care. She is widely regarded as one of Europe’s leading next‑generation clinical innovators in advanced radiotherapy.
Patricia (Patty) Díez
Patty Díez is a medical physicist who trained at Mount Vernon Cancer Centre and has worked in the National Radiotherapy Trials Quality Assurance (RTTQA) Group for over 20 years, striving to standardise treatment and raise radiotherapy standards through clinical trials. As lead clinical scientist in RTTQA, she has developed QA programmes for numerous trials for various indications including haematological malignancies, cervical cancer and oligometastatic disease. Patty’s current focus is on SABR trials (including STAMPEDE2, HALT, SOPRANO and TRAP) whilst leading the national SABR implementation programme.
Patty is an active member of the UK SABR Consortium Executive Committee, the UK SABR Education Working Group, the Global Harmonization Group and co-chairs the UK Haematology Radiotherapy Group. She is the editor of the UK SABR Consortium Guidelines and has recently co-authored the RCR Guidance on auto-contouring in radiotherapy. Patty is also contributing to the ESTRO consensus guidelines for the technical requirements for SABR as well as for the use of auto-segmentation in radiation oncology, and has a keen interest in teaching, serving as faculty for the EFOMP SABR MPE courses and all UK SABR Workshops.
David Palma
Dr. David Palma, MD, PhD is a Professor and Radiation Oncologist at Western University in London, Canada. He holds an MD from the University of Western Ontario, a Master’s Degree in Epidemiology from the Harvard School of Public Health, and a PhD from the VU University in Amsterdam. He has led several international randomized trials in radiation oncology, including the SABR-COMET and SABR-COMET10 randomized trials in oligometastatic disease, and the ORATOR and ORATOR2 trials in head and neck cancer. He is the chair of the Canadian Pulmonary Radiotherapy Investigators (CAPRI) group, which runs pragmatic radiation oncology trials in lung cancer. He is the author of the bestselling book Taking Charge of Cancer: What You Need to Know to Get the Best Treatment.